Acticor Biotech SAS

https://www.acticor-biotech.com

LinkedIn: https://www.linkedin.com/company/acticor-biotech

Acticor Biotech is a clinical stage biotechnology company, a spin-off of INSERM (the French National Institute of Health and Medical Research), dedicated to developing an innovative treatment for cardiovascular emergencies, including ischemic stroke. Acticor Biotech has been built on the expertise and research undertaken by its co-founders: Dr. Martine Jandrot-Perrus at INSERM Paris,Prof. Philippe Billiald at Paris-Sud University and Dr Gilles Avenard. Acticor Biotech is a partner in the BOOSTER consortium, dedicated to the management of, and novel treatments for, cerebrovascular accidents in emergency situations. Acticor Biotech is supported by a panel of European and International investors: Karista, Go Capital, Newton Biocapital, CMS Ventures, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and Armesa Foundation. *

	Start	2013-11-26 established (s-off)
	Group	Acticor Biotech (Group)
	Predecessor	Inserm (National Institute for Health and Medical Research, FR)
	Industry	antibody fragment (Fab)
	Industry 2	glenzocimab (ACT017)
	Person	Avenard, Gilles (Acticor Biotech 201612 CEO)

	Region	Paris
	Country	France
	Street	46 rue Henri Huchard Hôpital Bichat – Bâtiment Inserm U1148
	City	75877 Paris Cedex 18
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Euronext N.V.. (11/2/21). "Press Release: Acticor Biotech Lists on Euronext Growth Paris". Paris.

		Record changed: 2024-03-30